Common and specific gene signatures among three different endometriosis subtypes

Li Jiang¹, Mengmeng Zhang¹, Sixue Wang¹, Yuanyuan Han²,³ and Xiaoling Fang¹

¹ Department of Obstetrics and Gynecology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
² Center of Tree Shrew Germplasm Resources, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
³ Morning Star Academic Cooperation, Shanghai, China

ABSTRACT

Aims. To identify the common and specific molecular mechanisms of three well-defined subtypes of endometriosis (EMs): ovarian endometriosis (OE), peritoneal endometriosis (PE), and deep infiltrating endometriosis (DIE).

Methods. Four microarray datasets: GSE7305 and GSE7307 for OE, E-MTAB-694 for PE, and GSE25628 for DIE were downloaded from public databases and conducted to compare ectopic lesions (EC) with eutopic endometrium (EU) from EMs patients. Differentially expressed genes (DEGs) identified by limma package were divided into two parts: common DEGs among three subtypes and specific DEGs in each subtype, both of which were subsequently performed with the Kyoto Encyclopedia of Genes (KEGG) pathway enrichment analysis. The protein-protein interaction (PPI) network was constructed by common DEGs and five hub genes were screened out from the PPI network. Besides, these five hub genes together with selected interested pathway-related genes were further validated in an independent OE RNA-sequencing dataset GSE105764.

Results. A total of 54 EC samples from three EMs subtypes (OE, PE, DIE) and 58 EU samples were analyzed, from which we obtained 148 common DEGs among three subtypes, and 729 specific DEGs in OE, 777 specific DEGs in PE and 36 specific DEGs in DIE. The most enriched pathway of 148 shared DEGs was arachidonic acid (AA) metabolism, in which most genes were up-regulated in EC, indicating inflammation was the most common pathogenesis of three subtypes. Besides, five hub genes AURKB, RRM2, DTL, CCNB1, CCNB2 identified from the PPI network constructed by 148 shared DEGs were all associated with cell cycle and mitosis, and down-regulated in EC, suggesting a slow and controlled proliferation in ectopic lesions. The KEGG pathway analysis of specific DEGs in each subtype revealed that abnormal ovarian steroidogenesis was a prominent feature in OE; OE and DIE seems to be at more risk of malignant development since both of their specific DEGs were enriched in the pathways in cancer, though enriched genes were different, while PE tended to be more associated with dysregulated peritoneal immune and inflammatory microenvironment.

Conclusion. By integrated bioinformatic analysis, we explored common and specific molecular signatures among different subtypes of endometriosis: activated arachidonic acid (AA) metabolism-related inflammatory process and a slow and controlled...
proliferation in ectopic lesions were common features in OE, PE and DIE; OE and DIE seemed to be at more risk of malignant development while PE tended to be more associated with dysregulated peritoneal immune and inflammatory microenvironment, all of which could deepen our perception of endometriosis.

Subjects Bioinformatics, Gynecology and Obstetrics, Women’s Health
Keywords Bioinformatic analysis, Differentially expressed genes, Microarray, Endometriosis, Subtype

INTRODUCTION

Endometriosis (EMs), characterized by the growth of endometrium-type tissue outside the uterine cavity, is a common and usually chronic (long-term) inflammatory disorder, affecting 5–10% of women in their reproductive years (Zondervan et al., 2018). EMs is also considered as a phenotypically heterogeneous condition not only due to diverse symptoms, such as infertility, pelvic pain or dysmenorrhea but also different lesion locations, predominantly but not exclusively, in the pelvic compartment (Vercellini et al., 2014). Since the classic retrograde menstruation hypothesis (Sampson, 1927) that during menstrual uterine contractions, endometrial fragments via trans-tubal reflux flowed to implant onto the peritoneum and abdominal organs could not explain the fact that 76–90% of women experienced retrograde menstruation but not all of these women suffered from EMs (Blumenkrantz et al., 1981), there must exist other mechanisms facilitating the development of EMs. On the other hand, as early as 1997, Nisolle and Donnez provided morphological and histochemical evidence indicating that three main subtypes of endometriosis: ovarian endometriosis (OE), peritoneal endometriosis (PE), and deep infiltrating endometriosis (DIE), should be considered different entities, though they shared the histologic features of endometrial glands and stroma (Nisolle & Donnez, 1997). Thus, investigating the common and specific mechanisms among different EMs subtypes may provide new insight into the pathogenesis of endometriosis. However, due to the limited information as well as samples available from single cohorts, few integrative analyses of EMs subtypes were conducted.

Therefore, in this article, we analyzed the microarray datasets GSE7305 and GSE7307 of OE, E-MTAB-694 of PE, and GSE25628 of DIE to obtain common differentially expressed genes (DEGs) among three EMs subtypes along with specific DEGs in each subtype by comparing ectopic lesions (EC) with eutopic endometrium (EU) from EMs patients. Then, the Kyoto Encyclopedia of Genes (KEGG), protein-protein interaction (PPI) network and validation analysis were performed to analyze these common and specific DEGs (Fig. 1). Overall, all results were combined to promote further understanding of different EMs subtypes and reveal a more thorough landscape of EMs.

MATERIALS & METHODS

Data resources
The search for endometriosis-related microarray datasets was conducted in two public databases: Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and
Array-Express (https://www.ebi.ac.uk/arrayexpress/). The keywords: ‘endometriosis’, ‘endometrium’, ‘tissue’, ‘homo sapiens’ or ‘human’ respectively with ‘ovarian’, ‘peritoneal’, ‘DIE’, ‘deep’ or ‘infiltrating’ were employed to mine the datasets for three EMs subtypes. Additionally, all selected datasets were based on Affymetrix platforms to reduce the ‘platform effect’ due to different probe designs among different companies. Finally, four datasets were included: GSE7305 and GSE7307 for OE, E-MTAB-694 for PE, and GSE25628 for DIE (Table 1), all of which contained at least 8 samples for both ectopic lesions (EC) and eutopic endometrium (EU) from the EMs patients. A total of 54 EC samples from these datasets of different EMs subtypes and 58 EU samples were included.
Table 1 Basic information of the microarray datasets of three different EMs subtypes.

| Subtype | Accession | Platform | No. of probes | No. of samples (EU/EC, whether paired) | Tissue stage | References |
|---------|-----------|----------|---------------|----------------------------------------|--------------|------------|
| OE      | GSE7305   | GPL570 [HG-U133_Plus_2] | 54,675 | 20 (10/10, paired) | 2 Follicular phases and 8 Luteal phases | Hever et al. (2007) |
|         | GSE7307   | GPL570 [HG-U133_Plus_2] | 54,675 | 41 (23/18, unknown) | Unpublished | Unpublished |
| PE      | E-MTAB-694| GPL570: [HG-U133_Plus_2] | 54,675 | 35 (17/18, most were paired) | 8 Proliferative phases and 9 Secretory phases | Sohler et al. (2013) |
| DIE     | GSE25268  | GPL571: [HG-U133A_2] | 22,277 | 16 (08/08, paired) | 16 Proliferative phases | Crispi et al. (2013) |

Notes.
EMs, endometriosis; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis; EU, eutopic endometrium; EC, ectopic lesions.

Besides, all EC and EU samples in GSE7305 and GSE25628, as well as most in E-MTAB-694, were paired, meaning they were obtained from the same patients. The information on patients’ clinical characteristics in E-MTAB-694 for PE and GSE25628 for DIE were provided in the Tables S1 and S2 according to the original articles (Crispi et al., 2013; Sohler et al., 2013). However, the clinical information of patients was unavailable in the two datasets for OE: GSE7305 (not provided by the original article (Hever et al., 2007)) and GSE7307 (not originally published). Since our analysis did not involve any experiment on humans or animals directly, ethical approval was not necessary.

Data preprocessing
The raw data CEL files and group information of four datasets were downloaded from the GEO and Array-Express database. Firstly, the CEL files of GSE7305 and GSE7307 of subtype OE were combined into an integrated dataset, which was subsequently named the ‘merged OE dataset’. Then, CEL files of this ‘merged OE dataset’ as well as the individual PE dataset E-MTAB-694 and DIE dataset GSE25628 were read by ’Affy’ R package (Gautier et al., 2004), and further processed by the robust multi-array average (RMA) method for background correction, normalization, and expression calculation (Irizarry et al., 2003). Moreover, the ‘ComBat’ function in the SVA R package (Leek et al., 2012) was utilized to adjust the batch effects in the merged OE dataset, and then the principal component analysis (PCA) was applied to assess the performance of the batch effect adjustment. Also, the individual PE and DIE datasets were performed with PCA analysis to visualize sample distributions. Furthermore, probes were annotated according to the annotation files provided by Affymetrix official website (http://www.affymetrix.com/), and unmatched probes were abandoned.

Identification of DEGs
After pretreatment, R package limma (Ritchie et al., 2015) was applied to filtrate DEGs of these three datasets: the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and DIE dataset GSE25628, respectively, with the cutoff criteria: $|\log_2 \text{fold change (FC)}|>1$ and $p$-value $<0.05$. Additionally, the intersection analysis was conducted among three sets of DEGs.
KEGG pathway enrichment analysis
To explain common pathogenesis among three EMs subtypes (OE, PE, and DIE), KEGG pathway enrichment analysis of shared DEGs among the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and DIE dataset GSE25628 was performed by DAVID (http://david.abcc.ncifcrf.gov/), an online tool for comprehensive functional annotation of genes and proteins. Furthermore, to explore specific pathogenesis of these three subtypes, specific DEGs in each dataset were also conducted with KEGG pathway enrichment analyses by DAVID. A threshold of \( p \)-value < 0.05 was utilized to filter all KEGG pathways, which were also ranked by the \( p \)-value.

Validation of interested pathway-related genes in GSE105764
Considering all training datasets were comprised of microarray data, we intended to validate interested pathways related genes, for example, the most enriched pathway of common DEGs or representative pathways in the certain subtype, in RNA-sequencing datasets. However, due to the lack of PE and DIE RNA-sequencing datasets in searching results, we only performed the validation analysis in an OE RNA-sequencing dataset GSE105764 from the GEO database, which contained 8 paired EC and EU tissue samples based on GPL20301 (Illumina HiSeq 4000) (Zhao et al., 2018). The raw read counts were calculated by the DEseq2 R package (Love, Huber & Anders, 2014) to obtain the DEGs. Additionally, we also listed the expression of selected genes in the previously analyzed results of microarray datasets as a comparison.

PPI networks construction and identification of hub DEGs
The identified common DEGs among three EMs subtypes were uploaded to the online database STRING (http://string-db.org/; version 11.0) to explore their interactions at the protein level, with an interaction score > 0.4 as the cutoff value. Afterward, the PPI network was visualized in software Cytoscape (version 3.6.1) and analyzed by the 'Degree method' in plugin Cytohubba to identify the top 5 hub nodes in the network.

Validation analysis of hub DEGs in GSE105764
We also performed the validation analysis of the top 5 hub DEGs identified from the PPI network constructed of 148 common DEGs among three EMs subtypes in the OE RNA-sequencing dataset GSE105764. Additionally, we also listed the expression of these hub genes in the previously analyzed results of microarray datasets as a comparison.

RESULTS
Data preprocessing and Identification of DEGs
After combing the expression data, the merged OE dataset of GSE7305 and GSE7307 included 33 EU and 28 ovarian EC samples. Besides, the individual PE dataset E-MTAB-694 contained 17 EU and 18 peritoneal EC samples, and the individual DIE dataset GSE25628 comprised 8 EU and 8 deep infiltrating EC samples. After normalization of raw data in these datasets, boxplots were depicted, showing even mean values of gene expression in each sample. (Fig. S1). Moreover, the principal component analysis (PCA) was performed to examine the differences between EC and EU groups (Figs. 2A, 2B and 2C).
Figure 2  Principal component analysis (PCA) and identification of differentially expressed genes (DEGs) in each EMs subtype dataset. (A), (B), (C) After normalization of raw data in the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and the DIE dataset GSE25628, the principal component analysis (PCA) was performed to examine the differences between EC and EU groups; (D), (E), (F) Volcano plots of the distributions of DEGs between EC and EU in the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and the DIE dataset GSE25628. DEGs with log_{2}FC > 1 were shown in red dots; DEGs with log_{2}FC < −1 were in green dots (P < 0.05). No significantly changed genes are marked as black dots. EMs, endometriosis; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis; EC, ectopic lesions; EU, eutopic endometrium; log_{2}FC, log_{2} Fold Change.
Figure 3  Intersection analysis and KEGG pathway enrichment analysis of common and specific DEGs among OE, PE, and DIE. (A) Venn diagram of DEGs selected with $-\log_{2} FC > 1$ and $p$-value < 0.05 from the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and the individual DIE dataset GSE25628. These three datasets showed an overlap of 148 genes; (B) significantly enriched KEGG pathways of 148 shared DEGs specific to the merged OE dataset of GSE7305 and GSE7307; (C) significantly enriched KEGG pathways of 729 DEGs specific to the merged OE dataset of GSE7305 and GSE7307; (D) significantly enriched KEGG pathways of 777 DEGs specific to the individual PE dataset E-MTAB-694; (E) significantly enriched KEGG pathways of 36 DEGs specific to the individual DIE dataset GSE25628. All the entries were screened out with the $p$-value < 0.05 and ranked by $p$-value.

Subsequently, analyzed by the R package limma (Ritchie et al., 2015) with the threshold of $|\log_{2} FC| > 1$ and $p$-value < 0.05, a total of 744 upregulated as well as 626 downregulated DEGs were obtained from the merged OE dataset of GSE7305 and GSE7307, along with 731 upregulated and 772 downregulated DEGs from the individual PE dataset E-MTAB-694, and 268 upregulated and 77 downregulated DEGs from the individual DIE dataset GSE25628. Volcano plots were depicted for the visualization of DEGs in each dataset (Figs. 2D, 2E and 2F). The intersection analysis indicated that 148 genes were common to three datasets, 729 DEGs specific to the merged OE dataset, 777 DEGs specific to the individual PE dataset and only 36 DEGs specific to the individual DIE dataset owing to relatively fewer probes in this dataset, as shown in the Venn diagram (Fig. 3A).

**KEGG enrichment analysis of common and specific DEGs**

Based on the KEGG analysis from the online tool DAVID, 148 common DEGs were mainly enriched in the pathways of arachidonic acid (AA) metabolism, vascular smooth muscle contraction, drug metabolism-cytochrome P450, complement and coagulation cascades, tyrosine metabolism, according to the $p$-value ranking (Fig. 3B).

Likewise analyzed by DAVID, KEGG analysis showed that the top5 significantly enriched pathways of 729 specific DEGs in the merged OE dataset of GSE7305 and GSE7307 were staphylococcus aureus infection, PI3K-Akt signaling pathway, ovarian steroidogenesis, Rap1 signaling pathway, and cell adhesion molecules (CAMs) (Fig. 3C);
### Table 2: The top five enriched KEGG pathways of common DEGs among three EMs subtypes datasets and specific DEGs in each EMs subtype dataset.

| Category of DEGs | KEGG ID | Pathway description | Count | P-value | Enriched Genes |
|------------------|---------|---------------------|-------|---------|----------------|
| 148 common DEGs among the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and DIE dataset GSE25628 | hsa00590 | Arachidonic acid metabolism | 4 | 0.023854965 | GGT5, CYP2J2, PTGIS, PLA2G2A |
| | hsa04270 | Vascular smooth muscle contraction | 5 | 0.030857192 | ACTG2, AGTR1, ACTA2, PLA2G2A, MYL9 |
| | hsa00982 | Drug metabolism - cytochrome P450 | 4 | 0.031595883 | FMO1, FMO2, AOX1, ADH1B |
| | hsa04610 | Complement and coagulation cascades | 4 | 0.032797081 | C7, THBD, C3, CFH |
| | hsa00350 | Tyrosine metabolism | 3 | 0.048956335 | AOX1, ADH1B, AOC3 |

#### 729 specific DEGs in the merged OE dataset of GSE7305 and GSE7307

| Category of DEGs | KEGG ID | Pathway description | Count | P-value | Enriched Genes |
|------------------|---------|---------------------|-------|---------|----------------|
| | hsa05150 | Staphylococcus aureus infection | 14 | 2.19096E-07 | HLA-DQB1, ICAM1, C3AR1, C5AR1, MASP1, CFb, C1R, ITGB2, C1S, C1QC, HLA-DQA1, FGR2R2C, FGR2A, C2 |
| | hsa04151 | PI3K-Akt signaling pathway | 32 | 4.60007E-05 | FGFR2, FGFR3, OSMR, FG9, TNC, ITGA11, FG13, KIT, LPAR1, ITGB8, IL4R, COL27A1, PIK3AP1, ANGPT1, GNG2, GNG4, THBS1, COL11A1, INS, PPP2R2C, PIK3R1, FN1, MET, NMA1A, IGF1, CCN1, CDKN1A, ITGA6, PRLR, VEGFA, PDGFRA, JAK3 |
| | hsa04913 | Ovarian steroidogenesis | 10 | 0.00016359 | CYP17A1, PLA2G4A, PTGS2, CYP11A1, STAR, IGF1, SCAR1, ALOX5, INSR, BMP6 |
| | hsa04015 | Rap1 signaling pathway | 22 | 0.000172943 | FGFR2, FGFR3, FG9, MET, SIPA1L2, IGF1, ITGB2, FG13, LPAR1, KIT, DOCK4, RASSF1, PLCB4, ID1, VEGFA, PDGFRA, RAPGEF5, ANGPT1, THBS1, PLCB1, INS, PIK3R1 |
| | hsa04514 | Cell adhesion molecules (CAMs) | 17 | 0.00026996 | HLA-DQ81, ICAM1, PTPRC, MAG, CLDN4, CAD81, ITGB2, CLDN11, CDH3, HLA-DQA1, CD86, ITGA6, ITGB8, CNTN1, CNTNAP2, VCAN, JAM3 |

(continued on next page)
the top 5 significantly enriched pathways of 777 specific DEGs in the individual PE dataset E-MTAB-694 were cytokine-cytokine receptor interaction, cell adhesion molecules (CAMs), leukocyte trans-endothelial migration, regulation of lipolysis in adipocytes, and natural killer cell-mediated cytotoxicity (Fig. 3D); 36 specific DEGs in the individual DIE dataset GSE25628 were only enriched in two pathways: pathways in cancer and amoebiasis (Fig. 3E). Furthermore, the above-mentioned significant enriched pathways related genes were detailed in Table 2.

### Validation of interested pathway-related genes in GSE105764

Since endometriosis was defined as an inflammatory disorder (Bulun et al., 2019) and the top 1 enriched pathway of 148 common DEGs was the arachidonic acid (AA) metabolism pathway, a key pro-inflammatory pathway (Kuehl & Egan, 1980), we validated this pathway-related genes: GGT5, CYP2J2, PTGIS and PLA2G2A in the OE RNA-sequencing dataset GSE105764. The consistency results between microarray training datasets and the

---

**Table 2 (continued)**

| Category of DEGs | KEGG ID | Pathway description | Count | P-value | Enriched Genes |
|------------------|---------|---------------------|-------|---------|----------------|
|                  | hsa04060 | Cytokine-cytokine receptor interaction | 21    | 0.002513955 | CXCL1, TNFRSF21, IL2RB, CSF1, CXCL3, IL19, LIFR, CD40, CCL4, LEP, LIF, CCL13, TNFRSF10B, PBPB, CCL20, CXCR4, CCR2, TNFRSF18, CSF2RB, BMPR1B, CSF1R |
|                  | hsa04514 | Cell adhesion molecules (CAMs) | 14    | 0.005814763 | F11R, NRXN3, SELL, ICAM2, L1CAM, CD40, ITGA4, HLA-E, CDH5, SIGLEC1, SDC1, CLDN1, ESAM, CD28 |
|                  | hsa04670 | Leukocyte transendothelial migration | 12    | 0.00786069 | F11R, EZR, VAV3, CXCR4, MAPK13, CLDN1, ESAM, TXK, ITGA4, CDH5, PRKCB, VCL |
|                  | hsa04923 | Regulation of lipolysis in adipocytes | 8     | 0.007916063 | ADCY4, ADRB2, PLIN1, ADCY5, NPY1R, PRKG1, TSHR, LIPE |
|                  | hsa04650 | Natural killer cell-mediated cytotoxicity | 11    | 0.029482747 | CD48, PRF1, VAV3, TNFRSF10B, ICAM2, KIR2DS2, GZMB, KIR2DL3, KIR2DL2, KIR2DL4, PRKCB |
|                  | hsa05200 | Pathways in cancer | 5     | 0.013783298 | COL4A3, PTGER3, COL4A6, RAD51, F2R |
|                  | hsa05146 | Amoebiasis | 3     | 0.027515834 | COL4A3, ARG2, COL4A6 |

**Notes.**
KEGG, Kyoto Encyclopedia of Genes; DEGs, differentially expressed genes; EMs, endometriosis; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis.
RNA-sequencing validation dataset showed that most of these genes were found to be significantly higher in EC tissue than EU endometrium, except for CYP2J2 (Table 3). Moreover, besides the common pathogenetic pathways, each different subtype of EMs might possess its peculiar molecular signature. Since the validation dataset GSE105764 was an OE dataset and the inflammation in EMs were driven by estradiol (Bulun et al., 2019), we chose ovarian steroidogenesis—one representative pathway in subtype OE related genes to validate. The validation results showed that most genes in this pathway were significantly overexpressed in EC in subtype OE, almost consistent with that in the OE microarray training dataset, whereas with no significant difference between EU and EC in the individual PIE and DIE dataset (Table 4), which suggested ectopic tissue specificity and focal prominent aberrant hormonal environment in OE.

We also noticed that both specific DEGs in OE and DIE were enriched in the pathways in cancer, though enriched genes were different. The enriched genes in the ‘pathways in cancer’ in DIE were COL4A3, COL4A6, PTGER3, RAD51, F2R, while OE seems to be associated with ‘pathways in cancer’ mainly by PI3K-Akt signaling pathway-related genes, such as FN1, GNG2, KIT, PTGS2, PDGFRα, LPAR1, CCND1, ITGA6, FGFR3, VEGFA, PIK3R1, FGFR2, MET, indicated by both microarray training datasets and RNA-sequencing validation dataset (Tables S3 and S4).

**PPI network construction and hub DEGs identification**

By analyzing 148 common DEGs in database STRING, a PPI network with 99 nodes and 178 edges was constructed and then visualized in Cytoscape (Fig. 4A). Furthermore, the top 5 hub nodes: CCNB1, CCNB2, RRM2, DTL, AURKB were identified from this PPI network by using the Degree method in plugin Cytohubba (Fig. 4B).

**Validation analysis of hub DEGs in GSE105764**

As shown in Table 5, the expression trend of top 5 hub DEGs (CCNB1, CCNB2, RRM2, DTL, AURKB) was consistent in three subtypes—all under-expressed in ectopic lesions compared to eutopic endometrium, which was also further validated in the OE RNA-sequencing dataset GSE105764.

**DISCUSSION**

Endometriosis (EMs) was considered as a heterogeneous disease and its subtypes: ovarian endometriosis (OE), peritoneal endometriosis (PE), and deep infiltrating endometriosis (DIE) were likely to possess different aetiologies, which might require different diagnostic markers as well as treatments (Nisolle & Donnez, 1997; Gordts, Koninckx & Brosens, 2017). However, it is rare to see that all these three EMs subtypes were simultaneously included and analyzed in one study. To our best of knowledge, our article represents the first endeavor to analyze the common and specific molecular signatures among OE, PE, and DIE in a bioinformatic way based on effective microarray or RNA-sequencing datasets.

In this article, we conducted an integrative analysis of EMs mRNA microarray datasets belonging to three different subtypes: GSE7305 and GSE7307 of OE, E-MTAB-694 of PE, and GSE25628 of DIE. By analyzing DEGs between EU and EC samples, we found that
Table 3 The expression of the arachidonic acid metabolism pathway-related genes in microarray training datasets and the OE RNA-sequencing validation dataset GSE105764.

| Gene Symbol | Gene Description | OE RNA-sequencing dataset GSE105764 | The merged OE dataset of GSE7305 and GSE7307 | The individual PE dataset E-MTAB-694 | The individual DIE dataset GSE25628 |
|-------------|------------------|--------------------------------------|--------------------------------------------|----------------------------------|--------------------------------------|
|             |                  | Log2FC | P-Value | Log2FC | P-Value | Log2FC | P-Value | Log2FC | P-Value |
| PTGIS       | Prostaglandin I2 Synthase | 6.289598638 | 2.43946E-44 | 4.63128285 | 2.91622E-16 | 4.971203942 | 1.20213E-16 | 3.508766958 | 0.002253242 |
| PLA2G2A     | Phospholipase A2 Group IIA | 2.822326237 | 0.001074114 | 4.84961055 | 2.38055E-25 | 3.551202751 | 3.01372E-06 | 3.152761244 | 0.010549907 |
| GGT5        | Gamma-Glutamyltransferase 5 | 2.682418539 | 1.54252E-12 | 1.03319199 | 1.421E-13 | 1.031785388 | 5.90453E-07 | 1.32309443 | 0.006376396 |
| CYP2J2      | Cytochrome P450 Family 2 Subfamily J Member 2 | −6.239846138 | 1.75094E-27 | −1.142837781 | 1.79003E-09 | −1.850912918 | 9.66805E-09 | −1.160485084 | 0.02902089 |

Notes. Log2 FC, Log2 fold change; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis.
Table 4  The expression of one representative pathway in subtype OE–ovarian steroidogenesis related genes in microarray training datasets and the OE RNA-sequencing validation dataset GSE105764.

| Gene Symbol | Gene Description                                      | OE RNA-sequencing dataset GSE105764 | The merged OE dataset of GSE7305 and GSE7307 | The individual PE dataset E-MTAB-694 | The individual DIE dataset GSE25628 |
|-------------|--------------------------------------------------------|--------------------------------------|-----------------------------------------------|--------------------------------------|--------------------------------------|
|             |                                                        | Log2FC  | P-Value   | Log2FC  | P-Value   | Log2FC  | P-Value   | Log2FC  | P-Value   |
| STAR        | Steroidogenic Acute Regulatory Protein                | 3.844497923 | 3.67398E-10 | 5.549409967 | 5.35385E-30 | -0.691371832 | 0.030315396 | 0.2446853 | 0.854991  |
| BMP6        | Bone Morphogenetic Protein 6                          | 2.585401261 | 9.63142E-08 | 2.13686869 | 3.12026E-22 | 0.16812685 | 0.530786767 | 0.3323532 | 0.5156626 |
| CYP11A1     | Cytochrome P450 Family 11 Subfamily A Member 1         | 2.571939702 | 3.06172E-11 | 1.977665697 | 1.63051E-09 | -0.074703419 | 0.584259769 | -0.3281747 | 0.7447965 |
| SCARB1      | Scavenger Receptor Class B Member 1                    | 2.264263509 | 2.98276E-21 | 1.74100742 | 1.5326E-11 | 0.163414061 | 0.342902499 | 0.06680135 | 0.9171244 |
| ALOX5       | Arachidonate 5-Lipoxigenase                            | 1.932324569 | 2.01964E-06 | 1.113589966 | 2.23627E-05 | -0.030632071 | 0.87312448 | 0.2211488 | 0.7237545 |
| PTGS2       | Prostaglandin-Endoperoxide Synthase 2                 | 1.499535863 | 0.021110249 | 1.188644849 | 0.000423004 | -1.324453675 | 0.132193434 | -0.1371545 | 0.8414268 |
| CYP17A1     | Cytochrome P450 Family 17 Subfamily A Member 1         | 1.418757373 | 0.004554443 | 1.049381469 | 0.001851908 | 0.005875675 | 0.890819272 | -0.03743256 | 0.9750525 |
| INSR        | Insulin Receptor                                       | 0.381745388 | 0.192710241 | 1.285645953 | 7.63097E-12 | 0.02287573 | 0.938544186 | 0.387068073 | 0.208446551 |
| IGF1        | Insulin Like Growth Factor 1                           | -0.673337332 | 0.124361875 | -1.659370252 | 5.34224E-09 | -0.646869143 | 0.0069179 | -0.2747584 | 0.5370414 |
| PLA2G4A     | Phospholipase A2 Group IVA                              | -1.315828744 | 0.005668833 | -1.883142744 | 5.15085E-14 | -0.051607453 | 0.816803637 | 0.1022455 | 0.8456387 |

Notes.
OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis; Log2 FC, Log2 fold change.
Table 5  The expression of the top 5 hub genes identified from the PPI network in microarray training datasets and the OE RNA-sequencing validation dataset GSE105764.

| Gene symbol | Gene description                                      | OE RNA-sequencing dataset GSE105764 | The merged OE dataset of GSE7305 and GSE7307 | The individual PE dataset E-MTAB-694 | The individual DIE dataset GSE25628 |
|-------------|-------------------------------------------------------|-------------------------------------|---------------------------------------------|------------------------------------|-----------------------------------|
|             |                                                       | Log2FC, P-Value                      | Log2FC, P-Value                             | Log2FC, P-Value                   | Log2FC, P-Value                   |
| RRM2        | Ribonucleotide Reductase Regulatory Subunit M2        | −2.545059091, 5.65568E-06            | −2.902398466, 6.14787E-10                   | −3.521816066, 1.01611E-08         | −1.908309782, 0.01636418          |
| AURKB       | Aurora Kinase B                                       | −2.311429822, 3.34652E-05            | −1.42932862, 3.39568E-09                    | −1.911232107, 3.34734E-06         | −1.0990377, 0.039806461           |
| CCNB1       | Cyclin B1                                             | −1.856061436, 5.54985E-05            | −2.207580173, 3.967E-09                     | −2.161536326, 3.96789E-06         | −1.264483101, 0.047858003         |
| CCNB2       | Cyclin B2                                             | −1.825733268, 0.000537883            | −1.938433806, 3.70498E-09                   | −2.689873382, 7.46834E-07         | −1.446885624, 0.04121405          |
| DTL         | Denticleless E3 Ubiquitin Protein Ligase Homolog      | −1.228039999, 0.003406252            | −1.757599775, 1.88499E-08                   | −1.988898813, 5.57114E-07         | −1.372163345, 0.03263654          |

Notes. Log2 FC, Log2 fold change; OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis.
Figure 4  Protein-protein interaction (PPI) network construction and identification of hub nodes. (A) PPI network constructed by 148 shared DEGs among the merged OE dataset of GSE7305 and GSE7307, the individual PE dataset E-MTAB-694 and DIE dataset GSE25628. The red nodes represent upregulated genes and the green nodes represent downregulated genes. (B) Top 5 hub nodes (CCNB1, RRM2, DTL, CCNB2, AURKB) identified from the PPI network by using the Degree method in plugin Cytohubba. The nodes color changes gradually from yellow to red in ascending order according to the Degree ranking.

Full-size DOI: 10.7717/peerj.8730/fig-4

148 shared DEGs were common to three EMs subtypes, which were mainly involved in the pathways of arachidonic acid (AA) metabolism, vascular smooth muscle contraction, drug metabolism–cytochrome P450, complement and coagulation cascades, tyrosine metabolism revealed by KEGG enrichment analysis. Moreover, both the microarray training datasets and validation OE RNA-sequencing dataset showed that most of the genes in the top 1 enriched pathway—arachidonic acid (AA) metabolism pathway were activated in the EC tissues, except for CYP2J2.

In the arachidonic acid (AA) metabolism pathway, under the action of bioactive enzymes, substrate AA was catalyzed to generate endogenous eicosanoids such as prostaglandins (PGs), leukotrienes (LTs) and epoxyeicosatrienoic acids (EETs), which acted as mediators of various inflammatory disorders (Kuehl & Egan, 1980), including endometriosis (Benedetto, 1989; Monsivais et al., 2012; Sacco et al., 2012). PLA2G2A, a member of the phospholipase A2 family (PLA2) to catalyze the release of AA from membrane phospholipids, had been reported over-expressed in OE (Kocbek et al., 2015), DIE (Carrarelli et al., 2016) and PE (Lousse et al., 2010) ectopic lesions compared to normal or eutopic endometrium. The increased levels of PLA2G2A in endometriotic tissue would be responsible for providing AA for further PGs biosynthesis, such as PGE2, thus potentiating survival, migration, and invasion of endometriotic cells (Banu et al., 2008). The overexpression of PTGIS, functioning to convert prostaglandin H2 (PGH2) to prostaglandin I2 (PGI2), whose higher expression in the peritoneal fluid was observed in patients with endometriosis (Ylikorkala et al., 1984), had also been found a previous study (Monsivais et al., 2012). Under hypoxic conditions, PTGIS was reported to promote VEGF expression in human lung fibroblasts by producing PGI2 (Wang et al., 2013), whose enhanced production in ovarian endometrial cyst seemed to be associated with dysmenorrhea in endometriosis patients (Koike et al., 1992). GGT5 was responsible for converting leukotriene C4 (LTC4) to leukotriene D4 (LTD4), both of which were found with an increment of concentration
in menstrual blood from patients with primary dysmenorrhea (Rees et al., 1987) and the highly selective LTD4 receptor antagonist had an inhibiting effect on endometriotic implant growth in rat endometriosis model (Kiyak Altinbas et al., 2015). However, our analysis also revealed that in the ectopic lesions, CYP2J2 was under-expressed, an enzyme of cytochrome P450 (CYP) superfamily to metabolize AA into EETs, which exerted an anti-inflammatory effect by various mechanisms (Shahabi et al., 2014). Taken together, the activated arachidonic acid (AA) metabolism and its corresponding products seemed to promote inflammation in ectopic lesions, thus facilitating the development of EMs.

Interestingly, the 5 hub nodes RRM2, AURKB, DTL, CCNB1, CCNB2 identified from the PPI network constructed by 148 shared DEGs were all associated with cell cycle and mitosis, and down-regulated in the ectopic lesions in our analysis while always up-regulated in cancer tissues (Wang et al., 1997; Kolesar et al., 2009; Takashima et al., 2014; Kobayashi et al., 2015; Chieffi, 2018), thus promoting excessive proliferation, which suggested limited and controlled proliferative activity in EMs endometriotic lesions, distinct from cancerous proliferation feature. For example, RRM2, one of the subunits of ribonucleotide reductase complex providing precursors indispensable for DNA synthesis (Engström et al., 1985), was reported lowly expressed in EC compared to the EU in another genome-wide microarray study (Zafrakas et al., 2008), while its overexpression would enhance tumor angiogenesis and growth in multiple cancers (Zhang et al., 2009; Rahman et al., 2013). AURKB, a chromosomal passenger protein ensuring correct chromosome alignment and segregation in the mitosis (Kelly et al., 2010), was found low-expressed in OE ectopic tissues (Calcagno et al., 2011) whereas high-expressed in many tumors causing cell aneuploidy division (Giet, Petretti & Prigent, 2005). DTL, known as dentineless E3 ubiquitin-protein ligase homolog, was responsible for mediating the polyubiquitination and subsequent degradation of multiple regulators to ensure proper cell cycle progression (Higa et al., 2006), though seldom studied in EMs. However, the cyclin CCNB1, key regulator as well as CCNB2 in cell cycle controlling G2/M transition (Gong & Ferrell, 2010), were found up-regulated in ectopic tissue compared to eutopic endometrium in Tang et al. study (Tang et al., 2009), which was inconsistent with our analysis. This inconsistency might be explained by different detection methods and the intrinsic heterogeneity of EMs. Moreover, the phenomenon that most ectopic lesions contained sparse epithelial cells, which were abundant in eutopic endometrium and available to proliferate at a rapid speed, and mainly of stromal cells, whose multiplication rate was relatively mild, might result in the slow growth in ectopic tissue (Bulun et al., 2019).

Moreover, besides the common pathogenesis, we also explored the peculiar molecular signature in each subtype of EMs by the KEGG analysis of specific DEGs in different subtypes. For instance, most genes in the pathway of ovarian steroidogenesis were significantly up-regulated in EC in subtype OE while with no significant difference between EU and EC in the PE and DIE, which suggested ectopic tissue specificity and focal prominent aberrant hormonal environment in OE. Furthermore, the most up-regulated gene STAR in the pathway was proved to be correlated with the severity of OE and PE (Tian et al., 2009). That OE was regarded as an indicator of more severe pelvic and intestinal disease (Redwine, 1999) might be explained by this overactive ovarian steroidogenesis in OE since the steroid
hormone was primarily produced in the ovarian and then reached endometriotic lesions via blood circulation and follicular fluid at the time of ovulation.

We also noticed that both specific DEGs in OE and DIE enriched in ‘pathways in cancer’, though enriched genes were different: DIE was associated with the risk of malignant transformation by enriched genes COL4A3, COL4A6, RAD51, F2R, PTGER3, while OE mainly by those PI3K pathway-related genes, such as FN1, GNG2, KIT, PTGS2, PDGFRα, LPAR1, CCND1, ITGA6, FGFR3, VEGFA, PIK3R1, FGFR2, MET. However, PE was more likely related to dysregulated peritoneal immune and inflammatory microenvironment, indicated by its specific DEGs enriched pathways, such as maladjusted cytokine-cytokine receptor interaction, leukocyte trans-endothelial migration, and natural killer cell-mediated cytotoxicity. Whether PE could be regarded as more ‘superficial’ or ‘slight’ disease primarily affected by peritoneal fluid factors, than OE and DIE mainly influenced by blood or ovarian factors (Koninckx, Kennedy & Barlow, 1998), still needs further investigation. Hence, the landscape of specific signatures in each subtype were not clear enough in our analysis due to a relatively small number of available microarray datasets as well as limited information provided by these datasets, especially the DIE dataset based on a platform with fewer probes, which would be modified by obtaining more RNA-sequencing datasets including all three subtypes and considerable samples in future analysis.

However, our analysis still has some limitations. Firstly, due to the lack of RNA-sequencing datasets for PE and DIE, validation analysis was only performed in subtype OE. Secondly, since the uterine endometrium undergoes molecular signature changes throughout the menstrual cycle (Talbi et al., 2006), different cycle phases might be one of the confounding factors: DIE samples were all collected during the proliferative phase, all PE samples and OE samples in GSE7305 were collected during either proliferative or secretory phase, while cycle phases of OE samples in GSE7307 were unknown. Comparing the gene expression in each subdivided cycle phase respectively would provide an improved perspective. Additionally, the contamination of normal tissue sometimes was unavoidable during the sampling process, which in a way would lead to potentially controversial results. For example, in our results, the significant overexpression of ovarian steroidogenesis related genes in OE while not in PE and DIE ectopic tissues may be explained by the intrinsic differences among subtypes and/or the mixture of normal ovarian tissues. This needs further laboratory investigation in the future.

CONCLUSION

Through integrated bioinformatics analysis, we found that inflammation, especially arachidonic acid (AA) metabolism-related inflammatory process was the most common pathogenesis of OE, PE, and DIE. Besides, a slow and controlled proliferation in ectopic lesions was commonplace in these three EMs subtypes. Meanwhile, abnormal ovarian steroidogenesis was a prominent feature in OE; OE and DIE seemed to be at more risk of malignant development while PE tended to be more associated with dysregulated peritoneal immune and inflammatory microenvironment. All these findings could deepen our understanding of the common and specific molecular events in different subtypes in endometriosis.
ACKNOWLEDGEMENTS
We want to thank the GEO training course of Helix-Life for the training of bioinformatics analysis.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the National Natural Science Foundation of China (81671437, 81771558) and Hunan Provincial Natural Science Foundation, China (2016JC2049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81671437, 81771558.
Hunan Provincial Natural Science Foundation, China: 2016JC2049.

Competing Interests
Yuanyuan Han is employed by Center of Tree Shrew Germplasm Resources, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, and is also a member of the Morning Star Academic Cooperation (a non-profit organization as well as non-academic affiliation initiated by a group of voluntary scientific workers in China).

Author Contributions
• Li Jiang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Mengmeng Zhang analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Sixue Wang performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Yuanyuan Han performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Xiaoling Fang conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
Raw data are available at NCBI GEO: GSE7305, GSE7307, GSE25628, and GSE105764, and at ArrayExpress: E-MTAB-694.
Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.8730#supplemental-information.

REFERENCES

Banu SK, Lee J, Speights VO, Starzinski-Powitz A, Arosh JA. 2008. Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 149(3):1180–1189 DOI 10.1210/en.2007-1168.

Benedetto C. 1989. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecological Endocrinology 3(1):71–94 DOI 10.3109/09513598909152454.

Blumenkrantz MJ, Gallagher N, Bashore RA, Tenckhoff H. 1981. Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstetrics and Gynecology 57(5):667–670.

Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, Kohlmeier A, Yin P, Milad M, Wei J. 2019. Endometriosis. Endocrine Reviews 40(4):1048–1079 DOI 10.1210/er.2018-00242.

Calcagno A, Grassi T, Mariuzzi L, Marzinotto S, Londero AP, Orsaria M, Beltrami CA, Marchesoni D. 2011. Expression patterns of Aurora A and B kinases, Ki-67 and the estrogen and progesterone receptors determined using an endometriosis tissue microarray model. Human Reproduction 26(10):2731–2741 DOI 10.1093/humrep/der264.

Carrarelli P, Luddi A, Funghi L, Arcuri F, Batteux F, Dela Cruz C, Tosti C, Reis FM, Chapron C, Petraglia F. 2016. Urocortin and corticotrophin-releasing hormone receptor type 2 mRNA are highly expressed in deep infiltrating endometriotic lesions. Reproductive Biomedicine Online 33(4):476–483 DOI 10.1016/j.rbmo.2016.07.009.

Chieffi P. 2018. Aurora B: a new promising therapeutic target in cancer. Intractable & Rare Diseases Research 7(2):141–144 DOI 10.5582/irdr.2018.01018.

Crispi S, Piccolo MT, D’Avino A, Donizetti A, Viceconte R, Spyrou M, Calogero RA, Baldi A, Signorile PG. 2013. Transcriptional profiling of endometriosis tissues identifies genes related to organogenesis defects. Journal of Cellular Physiology 228(9):1927–1934 DOI 10.1002/jcp.24358.

Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. 1985. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. The Journal of Biological Chemistry 260(16):9114–9116.

Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307–315 DOI 10.1093/bioinformatics/btg405.

Giet R, Petretti C, Prigent C. 2005. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends in Cell Biology 15(5):241–250 DOI 10.1016/j.tcb.2005.03.004.
Gong D, Ferrell JE. 2010. The roles of cyclin A2, B1, and B2 in early and late mitotic events. *Molecular Biology of the Cell* 21(18):3149–3161 DOI 10.1091/mbc.e10-05-0393.

Gordts S, Koninckx P, Brosens I. 2017. Pathogenesis of deep endometriosis. *Fertility and Sterility* 108(6):872–885 DOI 10.1016/j.fertnstert.2017.08.036.

Hever A, Roth RB, Hevezi P, Marin ME, Acosta JA, Acosta H, Rojas J, Herrera R, Grigoriadis D, White E, Conlon PJ, Maki RA, Zlotnik A. 2007. Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. *Proceedings of the National Academy of Sciences of the United States of America* 104(30):12451–12456 DOI 10.1073/pnas.0703451104.

Higa LA, Banks D, Wu M, Kobayashi R, Sun H, Zhang H. 2006. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. *Cell Cycle* 5(15):1675–1680 DOI 10.4161/cc.5.15.3149.

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 4(2):249–264 DOI 10.1093/biostatistics/4.2.249.

Kelly AE, Ghenoiu C, Xue JZ, Zierhut C, Kimura H, Funabiki H. 2010. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. *Science* 330(6001):235–239 DOI 10.1126/science.1189505.

Kiykac Altinbas S, Tapisiz OL, Cavkaytar S, Simsek G, Oguztuzun S, Goktolga U. 2015. Is montelukast effective in regression of endometriotic implants in an experimentally induced endometriosis model in rats? *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 184:7–12 DOI 10.1016/j.ejogr2014.10.026.

Kobayashi H, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Miyamae M, Okajima W, Ohashi T, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. 2015. Overexpression of denteless E3 ubiquitin protein ligase homolog (DTL) is related to poor outcome in gastric carcinoma. *Oncotarget* 6(34):36615–36624.

Kocbek V, Bersinger NA, Brglez V, Mueller MD, Petan T, Rižner TL. 2015. Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients. *Gynecological Endocrinology* 31(3):214–218 DOI 10.3109/09553590.2014.975690.

Koike H, Egawa H, Ohtsuka T, Yamaguchi M, Ikenoue T, Mori N. 1992. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 46(2):133–137 DOI 10.1016/0952-3278(92)90219-9.

Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. 2009. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. *Cancer Chemotherapy and Pharmacology* 64(1):79–86 DOI 10.1007/s00280-008-0845-0.
Koninckx PR, Kennedy SH, Barlow DH. 1998. Endometriotic disease: the role of peritoneal fluid. *Human Reproduction Update* 4(5):741–751 DOI 10.1093/humupd/4.5.741.

Kuehl FA, Egan RW. 1980. Prostaglandins, arachidonic acid, and inflammation. *Science* 210(4473):978–984 DOI 10.1126/science.6254151.

Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. 2012. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28(6):882–883 DOI 10.1093/bioinformatics/bts034.

Lousse J-C, Defrère S, Colette S, Van Langendonckt A, Donnez J. 2010. Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. *Human Reproduction* 25(3):734–741 DOI 10.1093/humrep/dep408.

Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 15(12):550 DOI 10.1186/s13059-014-0550-8.

Monsivais D, Bray JD, Su E, Pavone ME, Dyson MT, Navarro A, Kakinuma T, Bulun SE. 2012. Activated glucocorticoid and eicosanoid pathways in endometriosis. *Fertility and Sterility* 98(1):117–125 DOI 10.1016/j.fertnstert.2012.03.030.

Nisolle M, Donnez J. 1997. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. *Fertility and Sterility* 68(4):585–596 DOI 10.1016/S0015-0282(97)00191-X.

Rahman MA, Amin ARMR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG, Shin DM. 2013. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. *Clinical Cancer Research: an Official Journal of the American Association for Cancer Research* 19(13):3416–3428 DOI 10.1158/1078-0432.CCR-13-0073.

Redwine DB. 1999. Ovarian endometriosis: a marker for more extensive pelvic and intestinal disease. *Fertility and Sterility* 72(2):310–315 DOI 10.1016/S0015-0282(99)00211-3.

Rees MC, DiMarzo V, Tippins JR, Morris HR, Turnbull AC. 1987. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. *The Journal of Endocrinology* 113(2):291–295 DOI 10.1677/joe.0.1130291.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43(7):e47 DOI 10.1093/nar/gkv007.

Sacco K, Portelli M, Pollacco J, Schembri-Wismayer P, Calleja-Agius J. 2012. The role of prostaglandin E2 in endometriosis. *Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology* 28(2):134–138 DOI 10.3109/09513590.2011.588753.

Sampson JA. 1927. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. *American Journal of Obstetrics and Gynecology* 14(4):422–469 DOI 10.1016/S0002-9378(15)30003-X.
Shahabi P, Siest G, Meyer UA, Visvikis-Siest S. 2014. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacology & Therapeutics 144(2):134–161 DOI 10.1016/j.pharmthera.2014.05.011.

Sohler F, Sommer A, Wachter DL, Agaimy A, Fischer OM, Renner SP, Burghaus S, Fasching PA, Beckmann MW, Fuhrmann U, Strick R, Strissel PL. 2013. Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesions. Reproductive Sciences 20(1):85–102 DOI 10.1177/1933719112451147.

Takashima S, Saito H, Takahashi N, Imai K, Kudo S, Atari M, Saito Y, Motoyama S, Minamiya Y. 2014. Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer. Tumour Biology 35(5):4257–4265 DOI 10.1007/s13277-013-1556-7.

Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. 2006. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 147(3):1097–1121.

Tang L, Wang T-T, Wu Y-T, Zhou C-Y, Huang H-F. 2009. High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. Fertility and Sterility 91(4):979–987 DOI 10.1016/j.fertnstert.2008.01.041.

Tian Y, Kong B, Zhu W, Su S, Kan Y. 2009. Expression of steroidogenic factor 1 (SF-1) and steroidogenic acute regulatory protein (StAR) in endometriosis is associated with endometriosis severity. The Journal of International Medical Research 37(5):1389–1395 DOI 10.1177/147323000903700513.

Vercellini P, Viganò P, Somigliana E, Fedele L. 2014. Endometriosis: pathogenesis and treatment. Nature Reviews. Endocrinology 10(5):261–275 DOI 10.1038/nrendo.2013.255.

Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. 1997. Overexpression of cyclin B1 in human colorectal cancers. Journal of Cancer Research and Clinical Oncology 123(2):124–127 DOI 10.1007/BF01269891.

Wang J, Ikeda R, Che X-F, Ooyama A, Yamamoto M, Furukawa T, Hasui K, Zheng C-L, Tajitsu Y, Oka T, Tabata S, Nishizawa Y, Eizuru Y, Akiyama S-I. 2013. VEGF expression is augmented by hypoxia-induced PGIS in human fibroblasts. International Journal of Oncology 43(3):746–754 DOI 10.3892/ijo.2013.1994.

Ylikorkala O, Koskimies A, Laatkainen T, Tenhunen A, Vii nikka L. 1984. Peritoneal fluid prostaglandins in endometriosis, tubal disorders, and unexplained infertility. Obstetrics and Gynecology 63(5):616–620.

Zafrakas M, Tarlatzis BC, Streichert T, Pournaropoulos F, Wölfe U, Smeets S, Wittek B, Grimbizis G, Brakenhoff R, Pantel K, Bontis J, Günes C. 2008. Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential. International Journal of Molecular Medicine 21(3):335–344.
Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B, Yen Y. 2009. Overexpression of RRM2 decreases thrombospondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Molecular Cancer 8:11 DOI 10.1186/1476-4598-8-11.

Zhao L, Gu C, Ye M, Zhang Z, Li LA, Fan W, Meng Y. 2018. Integration analysis of microRNA and mRNA paired expression profiling identifies deregulated microRNA-transcription factor-gene regulatory networks in ovarian endometriosis. Reproductive Biology and Endocrinology: RB & E 16(1):4.

Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. 2018. Endometriosis. Nature Reviews. Disease Primers 4(1):9 DOI 10.1038/s41572-018-0008-5.